We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice
Cookies settings I agree I disagreeCookies information
Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:
These settings will be kept for 24h
Bioxodes’ innovative pipeline includes a clinical-stage program for the prevention of thrombosis and neuroinflammation in patients with intracerebral hemorrhage (ICH). Bioxodes is also preparing a Phase 2 trial with BIOX-101 in ischemic stroke.
BIOX-101 demonstrates a powerful dual mode of action, targeting thromboinflammation at its source. It inhibits the activation of neutrophils – the human immune system’s first responders - and the release of neutrophil extracellular traps (NETs). It also inhibits Factors XIa and XIIa of the intrinsic coagulation pathway, exerting a powerful antithrombotic effect. Crucially, it does so without increasing bleeding.
In parallel, Bioxodes is developing a pipeline of drug candidates with the objectives to treat chronic thrombo-inflammatory and inflammatory diseases. The goal is to leverage the activity of BIOX-101 against neutrophil activation and NETs formation.
BIOX-101 is our lead asset, topping a pipeline of therapeutic candidates targeting thrombo-inflammatory diseases. We are currently preparing for a Phase 2b clinical trial of BIOX-101 in intracerebral hemorrhage (ICH), a condition with significant unmet medical need. BIOX-101 has received Orphan Drug Designation in both Europe and the U.S. for this indication.
In this short video, recorded with Bioxodes’ leadership, he highlights: BIOX-101 was safe in ICH patients, with no increase in hematoma volume—“the finding that struck me most.” Being able to administer BIOX-101 safely while helping prevent secondary thrombosis is “very, very important.” Edema data were promising; limiting edema expansion is a key driver of better outcomes. Watch the clip to learn more. The full webinar can be found on the investor page.
First-in-class clinical-stage therapeutic to treat intracerebral hemorrhage, an often lethal disease with no approved treatment.
Innovative pipeline targeting multiple thrombo-inflammatory indications and with ambitious discovery program.
Launching a potentially registrational Phase 2b trial for BIOX-101. Considering a Phase 2 trial for ischemic stroke.
Leuven, Belgium
Edinburgh, United Kingdom
Berlin, Germany
Bern, Switzerland
Lille, France
Caen, France
Brussels, Belgium
Hamilton, Canada
Boston, United-States
Biotech Showcase JP Morgan week
January 12, 2026
San Francisco, United States
Bioxodes will be attending the JP Morgan week in San Francisco from 12 to 14 January 2026. Our CEO has been invited to join the panel discussion on shaping the future of brain health on January 14th. Reach out to us if you want to connect during the event!
Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate
December 10, 2025
Gosselies
Belgen jagen op ‘kerkhof voor investeerders’ op behandeling tegen hersenbloeding
December 10, 2025
Belgium
Het Waalse biotechbedrijf Bioxodes tankt 5,5 miljoen euro om zijn kandidaat-behandeling voor intracerebrale bloedingen na een beroerte te testen. ‘We willen nog eens 80 miljoen euro ophalen’, zegt CEO Marc Dechamps.
Bioxodes lève 5,5 millions pour financer la suite de ses recherches autour de l'AVC
December 10, 2025
Belgium
La biotech wallonne à la recherche d'un traitement pour les victimes d'AVC hémorragiques vient de lever 5,5 millions d'euros. De quoi financer sa prochaine étude clinique.
Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.
